Valuation: Orexo AB

Market Cap 53Cr 5.49Cr 4.82Cr 4.48Cr 4.11Cr 7.73Cr 528.41Cr 7.85Cr 21Cr 259.79Cr 21Cr 20Cr 898.21Cr P/E 2026 *
-1.46x
P/E 2027 * -2.09x
Enterprise Value 43Cr 4.4Cr 3.87Cr 3.6Cr 3.3Cr 6.2Cr 424.16Cr 6.3Cr 17Cr 208.53Cr 17Cr 16Cr 721Cr EV / Sales 2026 *
22.5x
EV / Sales 2027 * 14.2x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 day-15.71%
Current month-15.71%
1 month-15.71%
3 months-20.98%
6 months-45.20%
Current year-45.20%
1 month 1.77
Extreme 1.77
1.77
Current year 1.77
Extreme 1.77
2.29
1 year 1.77
Extreme 1.77
3.23
3 years 1.08
Extreme 1.08
3.23
5 years 1.04
Extreme 1.04
4.02
10 years 1.04
Extreme 1.04
7.7
Manager TitleAgeSince
Chief Executive Officer 54 05/02/2013
Director of Finance/CFO 59 01/09/2022
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 64 01/01/2002
Director/Board Member 70 11/04/2019
Director/Board Member 62 01/04/2022
Change 5-day change 1-year change 3-year change Capi.($)
-15.71%0.00% - - 5.49Cr
+0.45%+2.80%+54.73%+22.34% 32TCr
+1.44%+2.09%+23.58%-11.87% 6.89TCr
+1.35%+5.29%+40.68%+87.27% 971.8Cr
+1.64%+0.15%+3.40%-2.15% 837.22Cr
+1.13%+1.51%-21.44%-4.05% 432.23Cr
+4.90%+5.79%-38.81%+21.37% 382.58Cr
-4.00%+0.71%-5.66%+12.85% 362.39Cr
-2.10%-3.83%+37.58%+53.03% 268.14Cr
-4.07%-2.45%-8.03%-10.93% 204.02Cr
Average -1.49%+1.42%+9.56%+18.65% 4.75TCr
Weighted average by Cap. +0.64%+2.63%+45.85%+17.49%

Financials

2026 *2027 *
Net sales 1.9Cr 19.59L 17.21L 16L 14.68L 27.59L 19Cr 28.01L 74.23L 9.27Cr 73.54L 71.95L 32Cr 2.75Cr 28.35L 24.9L 23.16L 21.25L 39.93L 27Cr 40.54L 1.07Cr 13Cr 1.06Cr 1.04Cr 46Cr
Net income -38Cr -3.87Cr -3.4Cr -3.16Cr -2.9Cr -5.44Cr -372.33Cr -5.53Cr -15Cr -183.05Cr -15Cr -14Cr -632.89Cr -27Cr -2.79Cr -2.45Cr -2.28Cr -2.09Cr -3.93Cr -268.57Cr -3.99Cr -11Cr -132.04Cr -10Cr -10Cr -456.53Cr
Net Debt -10Cr -1.08Cr -95.08L -88.42L -81.14L -1.52Cr -104.25Cr -1.55Cr -4.1Cr -51Cr -4.06Cr -3.98Cr -177.21Cr -14Cr -1.47Cr -1.29Cr -1.2Cr -1.11Cr -2.08Cr -141.98Cr -2.11Cr -5.59Cr -70Cr -5.53Cr -5.42Cr -241.34Cr
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise